Is Annovis Bio struggling financially?

Yes, by its own account. Annovis Bio told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

4/100

Critical

Sector: Biotech/Pharma
Market cap: $77.5M
Source filing: 10-Q 15 May 2026
Balance sheet: 30 Jun 2026

Cash runway

2months

If the burn speeds up

Empty by Aug 2026
4months

If it eases off

Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$18.7M

Cash burned over the last 12 months

$65.6M

What Annovis Bio told the SEC

March 31, 2026, is not sufficient to fund operations for the period through one year after the date of this filing and therefore, Management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern. Management’s plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management’s plans may also include the…

Annovis Bio, Inc., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

77.1% share-count increase The company issued stock. Each share now owns 43.5% less of the business than a year ago, before any change in the price.
Cash burn is increasing It is spending 52% more cash per year than it was, so the runway above shortens even if nothing else changes.

Cash runway

The runway math

What Annovis Bio told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt